Amphastar's 15min chart shows RSI overbought and Bollinger Bands narrowing.

Based on the 15-minute chart for Amphastar, the Relative Strength Index (RSI) has reached an overbought level, while the Bollinger Bands have narrowed as of August 14, 2025, at 13:30. This indicates that the stock price has experienced a rapid increase that is not supported by underlying fundamentals, and the magnitude of price fluctuations has decreased.

Amphastar Pharmaceuticals (AMPH) saw its stock price rise significantly following the FDA approval of its iron sucrose injection product, AMP-002. The approval marks a significant milestone for the company, positioning AMP-002 as an equivalent to Venofer, which generated approximately $515 million in sales over the past 12 months [1]. Needham & Co. upgraded the stock from Hold to Buy, setting a $36.00 price target, citing the potential for AMP-002 to generate $80-100 million in sales, targeting approximately two-thirds of the Venofer market not controlled by Fresenius [1].

The approval comes after a lengthy regulatory process, with the product having been in the Generic Drug User Fee Act (GDUFA) review since the second quarter of 2023 [1]. The approval ends what Needham described as a "2+yr regulatory purgatory" for the product [1]. Despite the positive news, Piper Sandler lowered its price target for Amphastar from $30.00 to $25.00, citing competitive headwinds, though it maintained a Neutral rating on the stock [1].

On August 14, 2025, the 15-minute chart for Amphastar showed the Relative Strength Index (RSI) reaching an overbought level, indicating that the stock price has experienced a rapid increase that is not supported by underlying fundamentals [3]. Additionally, the Bollinger Bands narrowed, suggesting that the magnitude of price fluctuations has decreased. This technical analysis suggests that the stock may be overvalued and could experience a pullback in the short term [3].

Amphastar's strong financial results for the second quarter of 2025, with earnings per share reaching 85 cents and revenues of $174.4 million, further support the company's growth prospects [2]. The company has also entered into an exclusive license agreement with Nanjing Anji Biotechnology for three proprietary peptide therapies targeting oncology and ophthalmology in the United States and Canada [2]. Despite these positive developments, investors should be cautious due to the overbought conditions indicated by the RSI and the narrowing of Bollinger Bands [3].

In conclusion, while the FDA approval of AMP-002 represents a significant milestone for Amphastar, investors should remain vigilant due to the overbought conditions indicated by technical indicators. The company's strong financial performance and robust pipeline of products provide a solid foundation for growth, but the potential for a short-term pullback should not be ignored.

References:
[1] https://ca.investing.com/news/analyst-ratings/needham-upgrades-amphastar-pharmaceuticals-stock-to-buy-on-iron-sucrose-approval-93CH-4151936
[2] https://www.ainvest.com/news/amphastar-pharmaceuticals-upgrade-buy-needham-amp-002-approval-2508/
[3] https://www.ainvest.com/news/amphastar-soars-8-9-groundbreaking-peptide-licensing-deal-fueling-biotech-surge-2508/